Precision Biosciences (DTIL) Profit After Tax (2018 - 2026)
Precision Biosciences (DTIL) reported Profit After Tax of -$18.4 million for Q1 2026, up 10.33% year-over-year from -$16.7 million in Q1 2025, and down 195.81% on a QoQ basis from $19.2 million in Q4 2025.
Precision Biosciences (DTIL) has 9 years of Profit After Tax data on file, last reported at -$18.4 million in Q1 2026.
- Quarterly Profit After Tax rose 10.33% year-over-year to -$18.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.5 million (down 102.33% YoY) and the FY2025 annual result came in at -$46.6 million, down 750.33% from the prior year.
- Profit After Tax eased to -$18.4 million in Q1 2026 per DTIL's latest filing, from $19.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at $32.7 million in Q2 2024 and bottomed at -$58.2 million in Q4 2022.
- The 5-year median for Profit After Tax is -$17.7 million (2024), against an average of -$15.1 million.
- The widest annual swing landed in 2024, when Profit After Tax jumped 375.41%; it then tumbled 339.46% in 2025.
- Tracing DTIL's Profit After Tax over 5 years: stood at -$58.2 million in 2022, then surged by 71.99% to -$16.3 million in 2023, then retreated by 8.94% to -$17.7 million in 2024, then jumped by 208.47% to $19.2 million in 2025, then plunged by 195.81% to -$18.4 million in 2026.
- Per Business Quant, the three latest DTIL Profit After Tax figures stand at -$18.4 million (Q1 2026), $19.2 million (Q4 2025), and -$21.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -18.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.44 Mn |
| Dec 31, 2025 | 19.25 Mn |
| Sep 30, 2025 | -21.77 Mn |
| Jun 30, 2025 | -23.52 Mn |
| Mar 31, 2025 | -20.57 Mn |
| Dec 31, 2024 | -17.75 Mn |
| Sep 30, 2024 | -16.43 Mn |
| Jun 30, 2024 | 32.75 Mn |
| Mar 31, 2024 | 8.59 Mn |
| Dec 31, 2023 | -16.29 Mn |
| Sep 30, 2023 | -12.11 Mn |
| Jun 30, 2023 | -11.89 Mn |
| Mar 31, 2023 | -25.06 Mn |
| Dec 31, 2022 | -58.16 Mn |
| Sep 30, 2022 | -15.69 Mn |
| Jun 30, 2022 | -31.04 Mn |
| Mar 31, 2022 | -28.17 Mn |
| Dec 31, 2021 | -22.29 Mn |
| Sep 30, 2021 | -11.28 Mn |
| Jun 30, 2021 | 21.66 Mn |
| Mar 31, 2021 | -18.69 Mn |
| Dec 31, 2020 | -23.45 Mn |
| Sep 30, 2020 | -26.02 Mn |
| Jun 30, 2020 | -32.70 Mn |
| Mar 31, 2020 | -26.84 Mn |
| Dec 31, 2019 | -20.92 Mn |
| Sep 30, 2019 | -20.74 Mn |
| Jun 30, 2019 | -19.44 Mn |
| Mar 31, 2019 | -31.78 Mn |
| Dec 31, 2018 | -15.44 Mn |
| Sep 30, 2018 | -9.76 Mn |
| Jun 30, 2018 | -11.83 Mn |
| Mar 31, 2018 | -9.01 Mn |